Deep Track Capital, LP
An institutional investment manager in GREENWICH, CT. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1856083.
- Reported value$6.87bn
- Positions67
Holdings: 67 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Guardant Health IncGH | COM | 40131M109 | 509 | 7.4% | 3,393,312 | Added+55,071 | |
| Immunovant IncIMVT | COM | 45258J102 | 360 | 5.2% | 9,341,151 | Reduced−2,185,820 | |
| Structure Therapeutics IncGPCR | SPONSORED ADS | 86366E106 | 254 | 3.7% | 4,740,072 | Added+460,224 | |
| Vaxcyte IncPCVX | COM | 92243G108 | 250 | 3.6% | 4,300,000 | Unchanged | |
| Alnylam Pharmaceuticals IncALNY | COM | 02043Q107 | 248 | 3.6% | 825,000 | New+825,000 | |
| Veradermics IncMANE | COMMON STOCK | 922967104 | 246 | 3.6% | 2,000,000 | Added+1,500,000 | |
| Tarsus Pharmaceuticals IncTARS | COM | 87650L103 | 231 | 3.4% | 3,666,768 | Added+66,768 | |
| Nuvalent Inc | COM | 670703107 | 220 | 3.2% | 1,783,322 | Added+406,998 | |
| Alkermes plc | SHS | G01767105 | 210 | 3.1% | 4,000,000 | Added+409,677 | |
| Ocular Therapeutix IncOCUL | COM | 67576A100 | 193 | 2.8% | 19,686,282 | Unchanged | |
| Biomarin Pharmaceutical IncBMRN | COM | 09061G101 | 189 | 2.8% | 3,307,481 | Added+2,157,481 | |
| Nurix Therapeutics IncNRIX | COM | 67080M103 | 188 | 2.7% | 7,736,455 | Added+1,391,211 | |
| Oruka Therapeutics IncORKA | COM | 687604108 | 183 | 2.7% | 1,926,000 | Reduced−108,203 | |
| Alumis IncALMS | COM | 022307102 | 179 | 2.6% | 6,348,558 | Reduced−424,037 | |
| Ionis Pharmaceuticals IncIONS | COM | 462222100 | 174 | 2.5% | 2,200,000 | Added+250,000 | |
| Compass Pathways plcCMPS | SPONSORED ADS | 20451W101 | 172 | 2.5% | 12,161,496 | Unchanged | |
| Vera Therapeutics IncVERA | CL A | 92337R101 | 172 | 2.5% | 4,000,000 | Reduced−106,067 | |
| Axsome Therapeutics Inc.AXSM | COM | 05464T104 | 171 | 2.5% | 700,000 | Reduced−400,000 | |
| Genmab A/SGMAB | SPONSORED ADS | 372303206 | 155 | 2.3% | 5,650,000 | Added+1,986,750 | |
| Moonlake ImmunotherapeuticsMLTX | CLASS A ORD | 61559X104 | 136 | 2.0% | 6,999,025 | Added+590,162 | |
| Hemab Therapeutics Holdings IncCOAG | COM SHS | 423494103 | 132 | 1.9% | 3,602,093 | New+3,602,093 | |
| Tango Therapeutics IncTNGX | COM | 87583X109 | 131 | 1.9% | 4,200,000 | Added+1,450,000 | |
| Definium Therapeutics IncDFTX | COM SHS | 24477V105 | 129 | 1.9% | 2,750,000 | Reduced−250,000 | |
| Grail IncGRAL | COM | 384747101 | 125 | 1.8% | 1,834,944 | Added+112,147 | |
| Bicara Therapeutics IncBCAX | COM | 055477103 | 122 | 1.8% | 4,100,000 | Added+37,500 | |
| Maze Therapeutics IncMAZE | COM | 578784100 | 111 | 1.6% | 3,732,569 | Added+255,007 | |
| Celldex Therapeutics Inc NewCLDX | COM NEW | 15117B202 | 109 | 1.6% | 2,939,151 | Added+1,655,172 | |
| LB Pharmaceuticals IncLBRX | COM SHS | 50180M108 | 109 | 1.6% | 3,352,804 | Unchanged | |
| MBX Biosciences IncMBX | COM | 55287L101 | 95.6 | 1.4% | 1,732,569 | Reduced−1,025,000 | |
| GH Research plc | ORDINARY SHARES | G3855L106 | 89.6 | 1.3% | 3,333,334 | New+3,333,334 | |
| Genmab A/SGMAB | SPONSORED ADS | 372303206 | 82.4 | 1.2% | 3,000,000 | Call | New+3,000,000 |
| Cogent Biosciences IncCOGT | COM | 19240Q201 | 77.4 | 1.1% | 2,000,000 | Added+1,000,000 | |
| Ataibeckley Inc | COM SHS | 04650F101 | 76.0 | 1.1% | 14,417,442 | Added+2,417,442 | |
| United Therapeutics Corp DelUTHR | COM | 91307C102 | 67.0 | 1.0% | 123,616 | New+123,616 | |
| Avalo Therapeutics IncAVTX | COM NEW | 05338F306 | 66.7 | 1.0% | 3,610,000 | New+3,610,000 | |
| Viridian Therapeutics IncVRDN | COM | 92790C104 | 66.0 | 1.0% | 3,592,740 | Added+2,198,796 | |
| Cytokinetics IncCYTK | COM NEW | 23282W605 | 59.6 | 0.9% | 700,000 | Reduced−674,320 | |
| Altimmune IncALT | COM NEW | 02155H200 | 58.5 | 0.9% | 19,250,000 | New+19,250,000 | |
| Personalis IncPSNL | COM | 71535D106 | 53.6 | 0.8% | 4,000,000 | Added+1,000,000 | |
| Aclaris Therapeutics IncACRS | COM | 00461U105 | 49.4 | 0.7% | 9,345,000 | Unchanged | |
| Cormedix IncCRMD | COM | 21900C308 | 49.3 | 0.7% | 6,274,076 | Unchanged | |
| Genedx Holdings CorpWGS | COM CL A | 81663L200 | 48.1 | 0.7% | 700,000 | New+700,000 | |
| Harrow IncHROW | COM | 415858109 | 41.2 | 0.6% | 969,000 | New+969,000 | |
| Corvus Pharmaceuticals IncCRVS | COM | 221015100 | 37.2 | 0.5% | 2,491,939 | Added+400 | |
| Solid Biosciences IncSLDB | COM NEW | 83422E204 | 35.6 | 0.5% | 3,565,062 | Unchanged | |
| Beam Therapeutics IncBEAM | COM | 07373V105 | 34.3 | 0.5% | 1,000,000 | Added+179,235 | |
| Dyne Therapeutics IncDYN | COM | 26818M108 | 33.3 | 0.5% | 1,500,000 | Reduced−500,000 | |
| Immix Biopharma IncIMMX | COM | 45258H106 | 28.6 | 0.4% | 2,775,000 | New+2,775,000 | |
| X4 Pharmaceuticals IncXFOR | COM NEW | 98420X202 | 27.5 | 0.4% | 5,878,757 | Reduced−460,778 | |
| Shattuck Labs IncSTTK | COM | 82024L103 | 25.7 | 0.4% | 3,706,734 | New+3,706,734 | |
| Mannkind CorpMNKD | COM NEW | 56400P706 | 25.6 | 0.4% | 6,000,000 | New+6,000,000 | |
| Century Therapeutics IncIPSC | COM | 15673T100 | 23.2 | 0.3% | 9,462,645 | Reduced−25,100 | |
| Generate Biomedicines IncGENB | COM SHS | 370920100 | 22.5 | 0.3% | 1,333,815 | New+1,333,815 | |
| Verastem IncVSTM | COM NEW | 92337C203 | 21.9 | 0.3% | 5,740,850 | Unchanged | |
| Kura Oncology IncKURA | COM | 50127T109 | 21.7 | 0.3% | 1,978,565 | Reduced−664,977 | |
| Enanta Pharmaceuticals IncENTA | COM | 29251M106 | 21.1 | 0.3% | 1,444,167 | Reduced−512,700 | |
| Nektar TherapeuticsNKTR | COM NEW | 640268306 | 20.9 | 0.3% | 300,000 | New+300,000 | |
| Olema Pharmaceuticals IncOLMA | COM | 68062P106 | 18.8 | 0.3% | 1,500,000 | New+1,500,000 | |
| Kailera Therapeutics IncKLRA | COMMON STOCK | 482931102 | 15.4 | 0.2% | 700,000 | New+700,000 | |
| Kardigan IncKARD | COM | 485925101 | 14.3 | 0.2% | 600,000 | New+600,000 | |
| Enliven Therapeutics IncELVN | COM | 29337E102 | 11.4 | 0.2% | 225,000 | New+225,000 | |
| Promis Neurosciences IncPMN | COM SHS | 74346M505 | 11.0 | 0.2% | 835,655 | Unchanged | |
| Immunocore Holdings plcIMCR | ADS | 45258D105 | 9.9 | 0.1% | 311,218 | Reduced−1,620,666 | |
| Xencor IncXNCR | COM | 98401F105 | 9.6 | 0.1% | 593,551 | New+593,551 | |
| Context Therapeutics IncCNTX | COM | 21077P108 | 4.1 | <0.1% | 7,419,355 | Unchanged | |
| Inventiva SAIVA | ADS | 46124U107 | 3.0 | <0.1% | 800,000 | Reduced−422,453 | |
| Aligos Therapeutics IncALGS | COM NEW | 01626L204 | 2.6 | <0.1% | 444,110 | Unchanged |
Sold out: 15 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| ANI Pharmaceuticals IncANIP | COM | 00182C103 | 0.0 | 0.0% | 0 | Sold out−600,000 | |
| Apellis Pharmaceuticals Inc | COM | 03753U106 | 0.0 | 0.0% | 0 | Sold out−4,532,374 | |
| Apogee Therapeutics Inc | COM | 03770N101 | 0.0 | 0.0% | 0 | Sold out−285,000 | |
| Billiontoone IncBLLN | CL A | 090168105 | 0.0 | 0.0% | 0 | Sold out−50,000 | |
| Bridgebio Pharma IncBBIO | COM | 10806X102 | 0.0 | 0.0% | 0 | Sold out−841,445 | |
| Centessa Pharmaceuticals plc | SPONSORED ADS | 152309100 | 0.0 | 0.0% | 0 | Sold out−3,158,041 | |
| Crescent Biopharma Inc. | COM | G2545C104 | 0.0 | 0.0% | 0 | Sold out−453,686 | |
| Cybin Inc | COM NEW | 23256X407 | 0.0 | 0.0% | 0 | Sold out−1,313,137 | |
| Engene Holdings Inc | COM | 29286M105 | 0.0 | 0.0% | 0 | Sold out−4,377,572 | |
| Geron CorpGERN | COM | 374163103 | 0.0 | 0.0% | 0 | Sold out−31,720,278 | |
| Janux Therapeutics IncJANX | COM | 47103J105 | 0.0 | 0.0% | 0 | Sold out−1,187,290 | |
| Larimar Therapeutics IncLRMR | COM | 517125100 | 0.0 | 0.0% | 0 | Sold out−1,500,000 | |
| Soleno Therapeutics Inc | COM | 834203309 | 0.0 | 0.0% | 0 | Sold out−1,078,710 | |
| SPDR Series Trust | STATE STREET SPD | 78464A870 | 0.0 | 0.0% | 0 | Put | Sold out−10,000,000 |
| Terns Pharmaceuticals Inc | COM | 880881107 | 0.0 | 0.0% | 0 | Sold out−1,073,877 |
Source: SEC EDGAR, Form 13F-HR, accession 0001856083-26-000004 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.